News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Esperion Therapeutics, Inc. Announces Positive Top-Line Results From Phase 2 Clinical Study of Novel Oral Therapy in Patients With Hypercholesterolemia and a History of Statin Intolerance


6/7/2013 9:53:26 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PLYMOUTH, Mich.--(BUSINESS WIRE)--Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced positive top-line results from a Phase 2a clinical study of its lead product candidate ETC-1002 in patients with hypercholesterolemia with a history of intolerance to two or more statins. The study met its primary endpoint, demonstrating that ETC-1002 lowered LDL-C by an average of 32 percent and was well tolerated. These data will be submitted for presentation at a future medical meeting and for publication in a peer-reviewed journal.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES